The implantable glucose sensor market size has grown rapidly in recent years. It will grow from $8.14 billion in 2025 to $9.34 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to rising diabetes prevalence, limitations of finger stick testing, early adoption of CGM devices, increasing healthcare expenditure, improvements in sensor accuracy.
The implantable glucose sensor market size is expected to see rapid growth in the next few years. It will grow to $16.05 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to growing demand for long term monitoring, integration with insulin delivery systems, expanding diabetic population, technological miniaturization, supportive reimbursement policies. Major trends in the forecast period include long duration implantable monitoring, finger prick free diabetes management, improved biocompatible sensor materials, continuous real time glucose tracking, rising adoption of home based monitoring.
The rising prevalence of diabetes is expected to drive the growth of the implantable glucose sensor market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood sugar or glucose levels. Its prevalence is increasing largely due to unhealthy lifestyle habits, such as reduced physical activity and higher consumption of calorie-dense foods, which raise the risk of developing type 2 diabetes. Implantable glucose sensors support diabetes management by providing continuous, long-term monitoring of blood glucose levels, making them especially useful for patients who require tight glucose control. By offering real-time data and alerts, these devices reduce the need for frequent finger-prick tests, enhancing patient convenience and improving overall health outcomes. For example, according to the UK’s National Health Service, in 2023, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of diabetes is fueling the expansion of the implantable glucose sensor market.
Major players in the implantable glucose sensor market are focusing on developing advanced devices, such as long-term implantable sensors, to improve patient convenience, health outcomes, and reduce the need for frequent device management. Long-term implantable sensors are medical devices placed under the skin to continuously measure glucose levels in the interstitial fluid over extended periods, unlike short-term sensors that require frequent replacement. For instance, in September 2024, Senseonics Holdings Inc., a US-based medical technology company, received FDA approval for the Eversense 365 continuous glucose monitoring system for individuals aged 18 and older with Type 1 or Type 2 diabetes. The system features a fully implantable sensor that lasts up to 365 days, providing continuous glucose readings and alerts for high and low glucose levels. It also connects to a mobile app and cloud platform, allowing patients and healthcare providers to remotely monitor glucose trends and make informed treatment decisions.
In May 2024, Senseonics Holdings Inc. partnered with Mercy to expand the clinical adoption of the Eversense continuous glucose monitoring system across Mercy’s network. This collaboration enables patients to benefit from long-duration implantable glucose monitoring, supported by remote patient monitoring and streamlined endocrinology workflows. Mercy is a US-based integrated healthcare organization offering hospital care, outpatient services, virtual care, and chronic disease management programs.
Major companies operating in the implantable glucose sensor market are Senseonics Holdings Inc., GlySens Incorporated, Profusa Inc., Abbott Laboratories, Dexcom Inc., Medtronic plc, Biolinq Inc., Nemaura Medical Inc., Integrated Sensing Systems Inc., WaveForm Technologies Inc., BioMems Solutions Inc., Echo Therapeutics Inc., Glucovation Inc., Know Labs Inc., Pacific Diabetes Technologies Inc., Metronom Health Inc., AliveCor Diabetes Inc., Pixelligent Technologies Inc., OrSense Ltd., Medtrum Technologies Inc.
North America was the largest region in the implantable glucose sensor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable glucose sensor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable glucose sensor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the implantable glucose sensor market by increasing costs of semiconductor components, biocompatible materials, and sensor electronics sourced globally. Asia-Pacific manufacturing hubs and North American import-dependent suppliers are most affected, particularly long-term implantable sensor segments. These cost pressures have slightly slowed adoption in price-sensitive regions. However, tariffs are also encouraging localized manufacturing and innovation in cost-efficient sensor designs, supporting long-term market resilience.
The implantable glucose sensor market research report is one of a series of new reports that provides implantable glucose sensor market statistics, including implantable glucose sensor industry global market size, regional shares, competitors with a implantable glucose sensor market share, detailed implantable glucose sensor market segments, market trends and opportunities, and any further data you may need to thrive in the implantable glucose sensor industry. This implantable glucose sensor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An implantable glucose sensor is a small medical device placed beneath the skin to continuously measure the body’s glucose levels and transmit the readings to an external monitor or smart device. It helps individuals manage diabetes more easily by offering real-time data without the need for frequent finger-prick tests. The device functions inside the body for an extended duration, providing a more convenient and consistent method for monitoring blood sugar.
The key product types of implantable glucose sensors include long-term implantable sensors and short-term implantable sensors. Long-term implantable sensors are glucose monitoring devices designed to remain under the skin for an extended period - typically weeks to months - to continuously measure blood glucose levels. These sensors utilize technologies such as enzymatic and non-enzymatic methods and are used for conditions such as type 1 diabetes, type 2 diabetes, and gestational diabetes. They serve end users including hospitals, clinics, home-care settings, and others.
The implantable glucose sensor market consists of sales of implantable glucose monitoring devices, biocompatible sensor probes, external data transmitters, wearable reader units, calibration accessories, and adhesive patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The implantable glucose sensor market size is expected to see rapid growth in the next few years. It will grow to $16.05 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to growing demand for long term monitoring, integration with insulin delivery systems, expanding diabetic population, technological miniaturization, supportive reimbursement policies. Major trends in the forecast period include long duration implantable monitoring, finger prick free diabetes management, improved biocompatible sensor materials, continuous real time glucose tracking, rising adoption of home based monitoring.
The rising prevalence of diabetes is expected to drive the growth of the implantable glucose sensor market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood sugar or glucose levels. Its prevalence is increasing largely due to unhealthy lifestyle habits, such as reduced physical activity and higher consumption of calorie-dense foods, which raise the risk of developing type 2 diabetes. Implantable glucose sensors support diabetes management by providing continuous, long-term monitoring of blood glucose levels, making them especially useful for patients who require tight glucose control. By offering real-time data and alerts, these devices reduce the need for frequent finger-prick tests, enhancing patient convenience and improving overall health outcomes. For example, according to the UK’s National Health Service, in 2023, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of diabetes is fueling the expansion of the implantable glucose sensor market.
Major players in the implantable glucose sensor market are focusing on developing advanced devices, such as long-term implantable sensors, to improve patient convenience, health outcomes, and reduce the need for frequent device management. Long-term implantable sensors are medical devices placed under the skin to continuously measure glucose levels in the interstitial fluid over extended periods, unlike short-term sensors that require frequent replacement. For instance, in September 2024, Senseonics Holdings Inc., a US-based medical technology company, received FDA approval for the Eversense 365 continuous glucose monitoring system for individuals aged 18 and older with Type 1 or Type 2 diabetes. The system features a fully implantable sensor that lasts up to 365 days, providing continuous glucose readings and alerts for high and low glucose levels. It also connects to a mobile app and cloud platform, allowing patients and healthcare providers to remotely monitor glucose trends and make informed treatment decisions.
In May 2024, Senseonics Holdings Inc. partnered with Mercy to expand the clinical adoption of the Eversense continuous glucose monitoring system across Mercy’s network. This collaboration enables patients to benefit from long-duration implantable glucose monitoring, supported by remote patient monitoring and streamlined endocrinology workflows. Mercy is a US-based integrated healthcare organization offering hospital care, outpatient services, virtual care, and chronic disease management programs.
Major companies operating in the implantable glucose sensor market are Senseonics Holdings Inc., GlySens Incorporated, Profusa Inc., Abbott Laboratories, Dexcom Inc., Medtronic plc, Biolinq Inc., Nemaura Medical Inc., Integrated Sensing Systems Inc., WaveForm Technologies Inc., BioMems Solutions Inc., Echo Therapeutics Inc., Glucovation Inc., Know Labs Inc., Pacific Diabetes Technologies Inc., Metronom Health Inc., AliveCor Diabetes Inc., Pixelligent Technologies Inc., OrSense Ltd., Medtrum Technologies Inc.
North America was the largest region in the implantable glucose sensor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the implantable glucose sensor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable glucose sensor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the implantable glucose sensor market by increasing costs of semiconductor components, biocompatible materials, and sensor electronics sourced globally. Asia-Pacific manufacturing hubs and North American import-dependent suppliers are most affected, particularly long-term implantable sensor segments. These cost pressures have slightly slowed adoption in price-sensitive regions. However, tariffs are also encouraging localized manufacturing and innovation in cost-efficient sensor designs, supporting long-term market resilience.
The implantable glucose sensor market research report is one of a series of new reports that provides implantable glucose sensor market statistics, including implantable glucose sensor industry global market size, regional shares, competitors with a implantable glucose sensor market share, detailed implantable glucose sensor market segments, market trends and opportunities, and any further data you may need to thrive in the implantable glucose sensor industry. This implantable glucose sensor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
An implantable glucose sensor is a small medical device placed beneath the skin to continuously measure the body’s glucose levels and transmit the readings to an external monitor or smart device. It helps individuals manage diabetes more easily by offering real-time data without the need for frequent finger-prick tests. The device functions inside the body for an extended duration, providing a more convenient and consistent method for monitoring blood sugar.
The key product types of implantable glucose sensors include long-term implantable sensors and short-term implantable sensors. Long-term implantable sensors are glucose monitoring devices designed to remain under the skin for an extended period - typically weeks to months - to continuously measure blood glucose levels. These sensors utilize technologies such as enzymatic and non-enzymatic methods and are used for conditions such as type 1 diabetes, type 2 diabetes, and gestational diabetes. They serve end users including hospitals, clinics, home-care settings, and others.
The implantable glucose sensor market consists of sales of implantable glucose monitoring devices, biocompatible sensor probes, external data transmitters, wearable reader units, calibration accessories, and adhesive patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Implantable Glucose Sensor Market Characteristics
3. Implantable Glucose Sensor Market Supply Chain Analysis
4. Global Implantable Glucose Sensor Market Trends and Strategies
5. Implantable Glucose Sensor Market Analysis of End Use Industries
7. Global Implantable Glucose Sensor Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Implantable Glucose Sensor Total Addressable Market (TAM) Analysis for the Market
9. Implantable Glucose Sensor Market Segmentation
10. Implantable Glucose Sensor Market Regional and Country Analysis
11. Asia-Pacific Implantable Glucose Sensor Market
12. China Implantable Glucose Sensor Market
13. India Implantable Glucose Sensor Market
14. Japan Implantable Glucose Sensor Market
15. Australia Implantable Glucose Sensor Market
16. Indonesia Implantable Glucose Sensor Market
17. South Korea Implantable Glucose Sensor Market
18. Taiwan Implantable Glucose Sensor Market
19. South East Asia Implantable Glucose Sensor Market
20. Western Europe Implantable Glucose Sensor Market
21. UK Implantable Glucose Sensor Market
22. Germany Implantable Glucose Sensor Market
23. France Implantable Glucose Sensor Market
24. Italy Implantable Glucose Sensor Market
25. Spain Implantable Glucose Sensor Market
26. Eastern Europe Implantable Glucose Sensor Market
27. Russia Implantable Glucose Sensor Market
28. North America Implantable Glucose Sensor Market
29. USA Implantable Glucose Sensor Market
30. Canada Implantable Glucose Sensor Market
31. South America Implantable Glucose Sensor Market
32. Brazil Implantable Glucose Sensor Market
33. Middle East Implantable Glucose Sensor Market
34. Africa Implantable Glucose Sensor Market
36. Implantable Glucose Sensor Market Competitive Landscape and Company Profiles
37. Implantable Glucose Sensor Market Other Major and Innovative Companies
40. Implantable Glucose Sensor Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Implantable Glucose Sensor Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses implantable glucose sensor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for implantable glucose sensor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable glucose sensor market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Long-term Implantable Sensors; Short-term Implantable Sensors2) By Technology: Enzymatic; Non-Enzymatic
3) By Application: Type 1 Diabetes; Type 2 Diabetes
4) By End-User: Hospitals; Clinics; Homecare Settings; Other End-Users
Subsegments:
1) By Long-Term Implantable Sensors: Enzyme-Based; Electrochemical; Fluorescence-Based2) By Short-Term Implantable Sensors: Minimally Invasive; Biocompatible Hydrogel-Based
Companies Mentioned: Senseonics Holdings Inc.; GlySens Incorporated; Profusa Inc.; Abbott Laboratories; Dexcom Inc.; Medtronic plc; Biolinq Inc.; Nemaura Medical Inc.; Integrated Sensing Systems Inc.; WaveForm Technologies Inc.; BioMems Solutions Inc.; Echo Therapeutics Inc.; Glucovation Inc.; Know Labs Inc.; Pacific Diabetes Technologies Inc.; Metronom Health Inc.; AliveCor Diabetes Inc.; Pixelligent Technologies Inc.; OrSense Ltd.; Medtrum Technologies Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Implantable Glucose Sensor market report include:- Senseonics Holdings Inc.
- GlySens Incorporated
- Profusa Inc.
- Abbott Laboratories
- Dexcom Inc.
- Medtronic plc
- Biolinq Inc.
- Nemaura Medical Inc.
- Integrated Sensing Systems Inc.
- WaveForm Technologies Inc.
- BioMems Solutions Inc.
- Echo Therapeutics Inc.
- Glucovation Inc.
- Know Labs Inc.
- Pacific Diabetes Technologies Inc.
- Metronom Health Inc.
- AliveCor Diabetes Inc.
- Pixelligent Technologies Inc.
- OrSense Ltd.
- Medtrum Technologies Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 9.34 Billion |
| Forecasted Market Value ( USD | $ 16.05 Billion |
| Compound Annual Growth Rate | 14.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
